Devonian Health Group, Inc. (TSE:GSD) has released an update.
Devonian Health Group’s subsidiary Altius Healthcare Inc. has launched Canada’s first authorized generic version of the gastroesophageal reflux disease (GERD) treatment, dexlansoprazole, which is anticipated to significantly boost the company’s presence in the Canadian prescription drug market. The release marks a key advancement in Devonian’s strategy to fund its botanical drug research aimed at addressing major diseases with unmet medical needs. The newly available generic drug is expected to substantially increase sales for Devonian, a botanical pharmaceutical corporation specializing in inflammatory-autoimmune diseases and cosmeceuticals.
For further insights into TSE:GSD stock, check out TipRanks’ Stock Analysis page.
